

Congress Agenda

Title:

Advances in Keratinocytic
Precancer Management

Objective:

1st International Actinic
Keratoses (AK) Congress



Date:

29 January 2027



Time:

09:00 - 17:15



Venue:

kHaus, Kasernenstrasse 8,
Basel, Switzerland



Scientific Committee

Prof. Lasse R. Braathen, Prof. Günther Hofbauer, Prof. Alexander Navarini,
Prof. Rolf-Markus Szeimies, Prof. Colin Morton

08:30 – 09:00 Registration & Coffee

09:00 – 09:10 Welcome & Introduction

Session 1:

Clinical spectrum, pathology and risk of progression

Chairs: Prof. Lasse R. Braathen & Prof. Alexander Navarini

09:10 – 09:30	Actinic keratosis: epidemiology, clinical spectrum and burden of disease	TBA
09:30 – 09:50	Field cancerisation: concept, biology and clinical implications	Prof. Lasse R. Braathen
09:50 – 10:10	Histopathology of actinic keratosis and keratinocytic intraepithelial neoplasia	Dr. Beda Mühleisen
10:10 – 10:30	The PRO score: can we predict which AK will progress?	TBA

10:30 – 11:00 Coffee break & Networking

Session 2:

Evidence-based treatment strategies

Chairs: Prof. Colin Morton & Prof. Rolf-Markus Szeimies

11:00 – 11:20	Lesion-directed therapies: cryotherapy, curettage and office-based approaches	Prof. Rolf-Markus Szeimies
11:20 – 11:35	Field-directed therapies: what do the meta-analyses really tell us?	Prof. Markus Heppt
11:35 – 11:50	Photodynamic therapy and daylight PDT: current role and patient selection	Prof. Colin Morton
11:50 – 12:05	Artificial daylight PDT	TBA
12:05 – 12:20	Enhancement of PDT by pretreatment (Laser, other)	TBA
12:20 – 12:40	AI meets actinic keratosis: LC-OCT-guided precision management	TBA

12:40 – 14:00 Lunch break & Networking

Congress Agenda

Title:

Advances in Keratinocytic
Precancer Management

Objective:

1st International Actinic
Keratosis (AK) Congress



Date:
29 January 2027



Time:
09:00 – 17:15



Venue:
kHaus, Kasernenstrasse 8,
Basel, Switzerland



Scientific Committee

Prof. Lasse R. Braathen, Prof. Günther Hofbauer, Prof. Alexander Navarini,
Prof. Rolf-Markus Szeimies, Prof. Colin Morton

Session 3:

Guidelines, special populations and mechanism-targeted prevention

Chairs: Prof. Markus Heppt & Prof. Günther Hofbauer

14:00 – 14:20	European and international guidelines: where do we agree, where do we differ?	Prof. Colin Morton
14:00 – 14:20	Tirbanibulin - longterm	Prof. Alexander Navarini
14:40 – 14:50	Topical rapamycin as a new option in the treatment of actinic keratosis	Prof. Günther Hofbauer
14:50 – 15:00	Topical bimiralisib: dual PI3K/mTOR inhibition in actinic keratosis	TBA
15:00 – 15:10	Treatment by collateral? AK during checkpoint inhibition	TBA
15:10 – 15:20	Microbioma and actinic keratosis	TBA

15:20 – 15:50 Coffee break & Networking

Session 4:

Controversies, case discussions and outlook

Chairs: Prof. Lasse R. Braathen & Prof. Alexander Navarini

15:50 – 16:50	Case-based expert discussion <i>Hypertrophic AK • extensive field cancerisation • actinic cheilitis • AK in organ transplant recipients • recurrence after therapy • intolerable pain • AK treatment in women •</i>	Prof. Lasse R. Braathen Prof. Markus Heppt Prof. Günther Hofbauer Prof. Colin Morton Prof. Rolf-Markus Szeimies
16:50 – 17:00	The five unanswered questions in AK research	Prof. Markus Heppt
17:00 – 17:10	Closing remarks and take-home messages	Prof. Lasse R. Braathe Prof. Günther Hofbauer

17:10 – 17:15 Farewell